The president of Mexico says that marijuana legalization will advance through Congress when it reconvenes next month—and he won’t stand in the way.

European building projects have relied on hempcrete to construct insulating, non-weight bearing infill walls since the 1990s.

Psychedelic drug therapies continue to win over new supporters. But the clock is ticking with our Mental Health Crisis…

Lygos, Inc. — a full-stack provider of sustainable specialty ingredients meant for cannabinoid-based consumer, nutraceutical, and pharmaceutical products —announced in a press release this week it had finalized a novel process of creating cannabinoids with proprietary fermentation and processing technology.

IntelGenX enters into agreement with ATAI Life Sciences to develop novel formulations of pharmaceutical-grade psychedelics.

The stocks of U.S.-focused operators have rallied while Canada-focused operators have underperformed in the second-quarter earnings season, closing the valuation gap on enterprise value-to-2021 sales. 

Mydecine is ready to start supplying GMP-quality psilocybin to advance psychedelics R&D.

United Kingdom Anti-Doping (UKAD) is imposing shorter bans for athletes who fail out-of-competition drug tests for non-performance enhancing drugs, including cannabis and cocaine, saying it was to put an “emphasis on athlete welfare,” the BBC reports.

Global Trac Solutions is developing a media partnership with Microdose.

In July, Virginia officially decriminalized cannabis possession of up to one ounce, a positive for cannabis reform and a benefit to the many residents of Virginia who are now a bit less apt to get jammed up in the system for using and possessing cannabis.